Kindred Biosciences To Raise $57.5 Mln In IPO; Pricing Terms Not Disclosed

(RTTNews) - Kindred Biosciences, Inc. announced that it has filed a registration statement on Friday on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $57.5 million in an initial public offering and the pricing terms were not disclosed.

The company, which was founded in 2012, plans to list on the NASDAQ under the symbol "KIN".

The Burlingame, california-based company intends to use offering net proceeds for the research and development of product candidates, manufacturing, marketing, distribution and commercialization of any approved products, other general corporate and working capital purposes.

BMO Capital Markets Corp. and Guggenheim Securities are the joint boook runners for the deal.

Kindred Biosciences is a veterinary biotechnology company that focuses on developing therapies for dogs, cats, and horses.